CHO
醣基生醫股份有限公司
CHO is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is CHO-H01 (Phase 1 / Phase 2; active not recruiting, Non-Hodgkin Lymphoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| CHO-H01 | — | Phase 1 / Phase 2; active not recruiting | Non-Hodgkin Lymphoma | Taiwan | 2026-08-17 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.